A MODERN VIEW ON THE PROBLEM OF DIAGNOSTICS OF PATIENTS WITH ANGIOFIBROMA OF THE NASOPHARYNX BY IDENTIFYING POLYMORPHISM OF THE GSTM 1 GENE

Abstract

Nasopharyngeal angiofibroma is a rare but potentially dangerous disease that requires accurate diagnosis and effective treatment methods. Current approaches to diagnosis are based primarily on visual and morphological methods, but the use of molecular markers, such as GSTM1 gene polymorphism, opens up new perspectives in this area. Genes involved in xenobiotic metabolism and antioxidant defense influence the development of tumor diseases, including angiofibroma. GSTM1 gene polymorphism, in particular its deletion, may be associated with an increased risk of tumor development, which emphasizes its importance as a diagnostic marker. The article provides an overview of existing diagnostic methods for nasopharyngeal angiofibroma and discusses the possibilities of using GSTM1 polymorphism to improve prognosis, individualize treatment, and increase the effectiveness of therapy. It is recommended to further study the role of this genetic marker in the pathogenesis of the disease and introduce it into clinical practice for more accurate diagnostics and development of personalized approaches to treatment.